FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies

FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies

Abstract In this review, we revisit the pivotal role of fibroblast growth factor receptor 3 (FGFR3) in bladder cancer (BLCA), underscoring its prevalence in both non‐muscle‐invasive and muscle‐invasive forms of the disease. FGFR3 mutations in up to half of BLCAs play a well‐established role in tumor...

Full description

Saved in:
Bibliographic Details
Main Authors: Maxim Noeraparast, Katarina Krajina, Renate Pichler, Dora Niedersüß‐Beke, Shahrokh F Shariat, Viktor Grünwald, Sascha Ahyai, Martin Pichler
Format: Article
Language:English
Published: Wiley 2024-10-01
Series:Cancer Communications
Subjects:
Bladder Cancer
Erdafitinib
FGFR inhibition
FGFR3 mutations
Resistance to Erdafitinib
Tumor Microenvironment
Online Access:https://doi.org/10.1002/cac2.12602
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cac2.12602

Similar Items